Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.

Rivkin, Saul E.; Green, S; O’Sullivan, Janet; Cruz, Anatolio B.; Abeloff, Martin D.; Jewell, William R.; Costanzi, John J.; Farrar, William B.; Osborne, C. Kent

doi:10.1200/jco.1996.14.1.46

Cited by 38 publications

(7 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is possible that PO combined with standard chemotherapy may further decrease primary breast cancer mortality. However, because this has not yet been well established in randomized trials, 37,38 we conservatively assumed that PO provides no additional protection from primary breast cancer recurrence and death. 39 Recent evidence suggests that PO may decrease breast cancer incidence by as much as 50% among cancer-free women with BRCA1 mutations irrespective of hormone replacement therapy usage.…”

Section: Effects Of Cancer Prevention Strategiesmentioning

confidence: 99%

Life Expectancy Gains From Cancer Prevention Strategies for Women With Breast Cancer and <EMPH TYPE="ITAL">BRCA1</EMPH> or <EMPH TYPE="ITAL">BRCA2</EMPH> Mutations

Schrag¹

2000

JAMA

202

View full text Add to dashboard Cite

show abstract

Section: Effects Of Cancer Prevention Strategiesmentioning

confidence: 99%

Life Expectancy Gains From Cancer Prevention Strategies for Women With Breast Cancer and <EMPH TYPE="ITAL">BRCA1</EMPH> or <EMPH TYPE="ITAL">BRCA2</EMPH> Mutations

Schrag¹

2000

JAMA

202

View full text Add to dashboard Cite

show abstract

“…On the contrary, results from randomized clinical trials did not demonstrate any difference in the prognosis of patients who received chemotherapy with or without concurrent pharmacological or surgical ovarian suppression. [55][56][57] This has recently been confirmed in the TEXT and SOFT trials showing similar survival outcomes with concurrent or sequential administration of GnRHa in premenopausal breast cancer patients with estrogen receptor-positive disease. 58 Regarding the second safety issue, it is known that chemotherapy-induced POI has a strong positive prognostic value in premenopausal women with estrogen receptor-positive breast cancer.…”

Section: Randomized Clinical Trials In Breast Cancer Patientsmentioning

confidence: 83%

Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?

Lambertini

Richard

Nguyen

et al. 2019

Clin Med�Insights�Reprod�Health

View full text Add to dashboard Cite

Chemotherapy-induced premature ovarian insufficiency (POI) is one of the potential drawbacks of chemotherapy use of particular concern for newly diagnosed premenopausal breast cancer patients. Temporary ovarian suppression obtained pharmacologically with the administration of a gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy has been specifically developed as a method to counteract chemotherapy-induced gonadotoxicity with the main goal of diminishing the risk of POI. In recent years, important clinical evidence has become available on the efficacy and safety of this strategy that should now be considered a standard option for ovarian function preservation in premenopausal breast cancer patients, including women who are not interested in conceiving after treatment or that would not be candidates for fertility preservation strategies because of their age. Nevertheless, in women interested in fertility preservation, this is not an alternative to gamete cryopreservation, which remains as the first option to be offered. In this setting, temporary ovarian suppression with GnRHa during chemotherapy should be also proposed following gamete cryopreservation or to women who have no access, refuse, or have contraindications to surgical fertility preservation techniques. In this article, we present an overview about the role of temporary ovarian suppression with GnRHa during chemotherapy in breast cancer patients by addressing the available clinical evidence with the aim of identifying both the best candidates for the use of this strategy and the still existing gray zones requiring further investigation.

show abstract

“…2 ). Overall, 11 published studies 16 18 19 20 21 22 23 24 25 26 27 fulfilled the criteria for eligibility and were included in the review ( Table 1 ).…”

Section: Resultsmentioning

confidence: 99%

Evaluating the Survival Benefit Following Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor Positive Early Breast Cancer

Qiu

Huang³

et al. 2016

Sci Rep

View full text Add to dashboard Cite

There are divergent opinions regarding the use of ovarian function suppression or ablation (hereafter, OFS) in hormone receptor positive early breast cancer patients. In order to clarify the survival benefit of OFS, a meta-analysis was performed. The result is that use of OFS was more effective than no OFS on DFS (the pooled relative risk (pRR) = 0.86; 95% CI: 0.75–0.96) and on OS (pRR = 0.79; 95% CI: 0.70–0.89). In subgroup analysis, we found that increased DFS was positively associated with patients who had received chemotherapy (pRR = 0.85; 95% CI: 0.74–0.96), who were lymph node negative (pRR = 0.74; 95% CI: 0.61–0.91) and were less than 40 years old (pRR = 0.71; 95% CI: 0.59–0.83). There was a significant difference in OS between the groups receiving chemotherapy (pRR = 0.73; 95% CI: 0.58–0.89) or for patients less than 40 years old (pRR = 0.52; 95% CI: 0.18–0.87). The use of OFS also produces statistical differences in the occurrence of the side-effects; severe hot flashes (pRR = 2.32; 95% CI: 1.36–3.97), and hypertension (pRR = 1.54; 95% CI: 1.12–2.12). In general, OFS should be considered as one treatment for hormone receptor positive premenopausal early breast cancer patients who have received chemotherapy and are less than 40 years old. We also should pay attention to the side-effects and weigh the advantages and disadvantages before deciding on using OFS.

show abstract

Adjuvant CMFVP versus adjuvant CMFVP plus ovariectomy for premenopausal, node-positive, and estrogen receptor-positive breast cancer patients: a Southwest Oncology Group study.

Cited by 38 publications

References 9 publications

Life Expectancy Gains From Cancer Prevention Strategies for Women With Breast Cancer and <EMPH TYPE="ITAL">BRCA1</EMPH> or <EMPH TYPE="ITAL">BRCA2</EMPH> Mutations

Life Expectancy Gains From Cancer Prevention Strategies for Women With Breast Cancer and <EMPH TYPE="ITAL">BRCA1</EMPH> or <EMPH TYPE="ITAL">BRCA2</EMPH> Mutations

Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?

Evaluating the Survival Benefit Following Ovarian Function Suppression in Premenopausal Patients with Hormone Receptor Positive Early Breast Cancer

Contact Info

Product

Resources

About